PACS Group Inc ( (PACS) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PACS Group Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The delay is primarily due to an ongoing independent investigation by the company’s Audit Committee, assisted by external counsel, into recent third-party allegations. This investigation has necessitated the delay of the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as earlier reports. PACS Group Inc. plans to file the delayed reports as soon as practicable, following the completion of the investigation. The company has stated that there are no anticipated significant changes in financial results from the previous fiscal year. The notification was signed by Derick Apt, the Chief Financial Officer, on May 16, 2025, indicating the company’s commitment to resolving the issue and maintaining compliance.
The most recent analyst rating on (PACS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on PACS Group Inc stock, see the PACS Stock Forecast page.
Spark’s Take on PACS Stock
According to Spark, TipRanks’ AI Analyst, PACS is a Neutral.
The overall score for PACS Group Inc is moderate due to strong revenue growth counterbalanced by high financial leverage and negative technical indicators. Regulatory risks from noncompliance with NYSE requirements further impact the score. Limited valuation data and lack of earnings call insights add to the uncertainty surrounding the stock.
To see Spark’s full report on PACS stock, click here.
More about PACS Group Inc
Average Trading Volume: 537,310
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.7B
For a thorough assessment of PACS stock, go to TipRanks’ Stock Analysis page.